Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human DR4 Antibodies:
anti-Mouse (Murine) DR4 Antibodies:
anti-Monkey DR4 Antibodies:
Go to our pre-filtered search.
our results demonstrated that nanovectorization of TRAIL with BNNTs enhanced its binding to both DR4 (show HLADRB4 Antibodies) and DR5 (show TNFRSF10B Antibodies) receptors at 37 degrees C. Our novel nanovector could potentially be used for delivering TRAIL to cells for cancer treatment
By downregulating TRAIL-R1, TGFbeta1 (show TGFB1 Antibodies) may not only promote tumor escape from immune surveillance but also negatively impact on TRAIL- or TRAIL-R1-based therapy regimens for treatment of Pancreatic ductal adenocarcinoma.
Results show that downregulation of DR4 (show HLADRB4 Antibodies) and DR5 (show TNFRSF10B Antibodies) by SLC26A2 (show SLC26A2 Antibodies) confers resistance to TRAIL.
BAY61-3606 sensitizes colon cancer cells to TRAIL-induced apoptosis by up-regulating DR4 (show HLADRB4 Antibodies) expression in p53 (show TP53 Antibodies)-dependent manner and inhibiting NF-kappaB (show NFKB1 Antibodies) activity.
findings together highlight a previously undiscovered mechanism that positively regulates DR4 (show HLADRB4 Antibodies) expression through activation of the MEK (show MAP2K1 Antibodies)/ERK (show EPHB2 Antibodies)/AP-1 (show FOSB Antibodies) signaling pathway.
results suggest that the altered TRAIL, DR4 (show HLADRB4 Antibodies) alleles and sTRAIL levels may be associated with some other potential biomarkers for vitiligo (show MITF Antibodies)
The nanovectorization of TRAIL enhanced its binding to both DR4 (show HLADRB4 Antibodies) and DR5 (show TNFRSF10B Antibodies) receptors at 37 degrees C and could potentially sensitized cancer cells to TRAIL induced apoptosis through simultaneous activation of DR4 (show HLADRB4 Antibodies) and DR5 (show TNFRSF10B Antibodies) as described in this paper for the non-small lung carcinoma cell line (H1703), the two hepatocarcinoma cell lines (SK-Hep1, HUH) and the colon carcinoma cell line (HCT116WT).
Pro-survival effects by NF-kappaB (show NFKB1 Antibodies), Akt (show AKT1 Antibodies) and ERK(1 (show MAPK3 Antibodies)/2) and anti-apoptosis actions by Six1 (show SIX1 Antibodies) disrupt apoptotic functions of TRAIL-Dr4 (show HLADRB4 Antibodies)/5 pathway in ovarian cancer, which may explain why up-regulated DR4 (show HLADRB4 Antibodies) and DR5 (show TNFRSF10B Antibodies) in ovarian cancer are associated with poor prognosis and low survival ratio of the patients.
Bee venom inhibits colon cancer cell growth, and these anti-proliferative effects may be related to the induction of apoptosis by activation of DR4 (show HLADRB4 Antibodies) and DR5 (show TNFRSF10B Antibodies) and inhibition of NF-kappaB (show NFKB1 Antibodies) activity.
study involving a relatively large sample size showed that TNFRSF10 eQTL (show EQTN Antibodies) SNPs within lncRNAs might influence both hepatocellular carcinoma development and HBV infection
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.
TNF-related apoptosis-inducing ligand receptor 1
, TRAIL receptor 1
, cytotoxic TRAIL receptor
, death receptor 4
, tumor necrosis factor receptor superfamily member 10A
, tumor necrosis factor receptor superfamily member 10a variant 2